Gyre Therapeutics (NASDAQ: GYRE) net income
Gyre Therapeutics reported a net profit of $9.9m for fiscal 2025, 44.8% less than in fiscal 2024 ($17.9m). Its net margin was 8.5%. Earnings per share were $0.06.
Gyre Therapeutics's best year of the last 10 was fiscal 2024. The biggest drop was in fiscal 2025, −44.8%. It reported a loss in 7 of those 10 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | $9.9m | −44.8% | 8.5% | $0.06 |
| 2024 | $17.9m | — | 16.9% | $0.14 |
| 2023 | −$85.5m | −2,081.5% | −75.3% | −$1.41 |
| 2022 | $4.3m | — | 4.2% | — |
| 2021 | −$87.9m | — | −1,198.3% | −$2.87 |
| 2020 | −$56.2m | — | −268.5% | — |
| 2019 | −$55.2m | — | — | — |
| 2018 | −$30.1m | — | −500,916.7% | — |
| 2017 | −$21.6m | — | −2,118.0% | — |
| 2016 | −$16.9m | — | — | — |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Gyre Therapeutics net income compared with its sector
By net income for its latest fiscal year, Gyre Therapeutics ranks 161st of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of Gyre Therapeutics, 8.5%.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 159th | Electromed | $11.3m | 15.3% |
| 160th | Utah Medical Products | $11.3m | 29.3% |
| 161st | Gyre Therapeutics | $9.9m | 8.5% |
| 162nd | Artivion | $9.8m | 2.2% |
| 163rd | LifeStance Health Group | $9.7m | 0.7% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Gyre Therapeutics
- How much did Gyre Therapeutics earn in fiscal 2025?
- Gyre Therapeutics reported a net profit of $9.9m for fiscal 2025. In fiscal 2024 it reported a net profit of $17.9m.
- What are the earnings per share of Gyre Therapeutics?
- They were $0.06 in fiscal 2025, compared with $0.14 in fiscal 2024.
- What is the net margin of Gyre Therapeutics?
- In fiscal 2025 its net profit was 8.5% of its revenue.
- What was the most profitable year for Gyre Therapeutics?
- Of its last 10 fiscal years, fiscal 2024, with $17.9m.
- Where does Gyre Therapeutics rank in its sector by net income?
- It ranks 161st of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Gyre Therapeutics come from?
- From the annual report (Form 10-K) that Gyre Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Gyre Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Gyre Therapeutics: the Gyre Therapeutics page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.